Immune-checkpoint inhibitor associated HP has been identified as potentially severe events through inhibiting the cytotoxic T-lymphocyte antigen (CTLA)−4 pathways and programmed cell death protein 1 (PD1) in patients with cancer [31–34]. This evidence concerns the gene CTLA4 and hypersensitivity pneumonitis.